INTRODUCTION

Obstructive sleep apnea (OSA) is a disorder characterized with loud snoring, fragmented sleep, recurrent airway obstruction during sleep, and drowsiness in daytime that adversely affects quality of life.1 The upper airway obstruction can occur during sleep, as a result of various conditions. Anatomic variations of airline-related sections in development, being overweight, and prone position can be some of the causes of OSA. These patients may experience cardiac arrhythmias, angina, myocardial infarction, mental problems, and also OSA can lead to more serious consequences, such as traffic accidents. Snoring or subjective data are not sufficient for diagnosis. Definitive diagnosis can only be done with polysomnography (PSG), which is performed by sleeping in a sleep laboratory.1-4

The treatment of OSA extends from surgical treatment to conservative treatment. Obstructive sleep apnea therapy can be summarized in four main categories: Behavior modification, the use of continuous positive airway pressure (CPAP) device, the use of oral appliances, and surgical approaches.1,3,5 With mandibular advancement device (MAD) treatment, the goal is to prevent the narrowing of the airway during sleep by positioning the mandible in a forward place.6 When compared with other methods of treatment of OSA, oral appliances have advantages, such as being able to be better tolerated by patients, cheaper, simple, noninvasive, reversible, and reduced clinic hours.3 Oral appliances are an alternative to CPAP for the treatment of OSA. Especially, MAD is an alternative treatment in patients who cannot tolerate CPAP or bilevel device.

In this clinical report, the outcome of treatment MAD and bilevel device for a patient who is intolerant to bilevel PAP treatment with severe OSA is presented. The therapeutic effects were analyzed.

CASE REPORT

A 70-year-old man was admitted to the Department of Prosthodontics, Faculty of Dentistry, Hacettepe University, Ankara, Turkey, with a history and diagnosis of loud snoring and OSA. Previously, he was examined in the Sleep Disorders Center of Atatürk Chest Diseases and Chest Surgery Education and Research Hospital and then referred to our clinic. The patient underwent a full-night PSG, using the Compumedics Voyager Digital Imaging 44-Channel E-Series System (Compumedics®, Melbourne, Victoria, Australia). Sleep stages as well as respiratory parameters were scored according to the standard criteria of the American Academy of Sleep Medicine. The patient was diagnosed with severe OSA with rhythmic limb movement in sleep, and having respiratory disturbance index (RDI) of 62.7.

An extraoral and intraoral examination was made. Intermaxillary relationship was evaluated using diagnostic casts and panoramic radiograph. There was no problem with the teeth and the periodontal tissues; class I occlusion was observed. Palpation and auscultation were applied for temporamandibular joint evaluation. He had no periodontal and temporomandibular diseases. Muscle palpation and motion range of the jaw, such as maximum opening (45 mm), lateral and protrusive movements (>7 mm) were also evaluated. Neck size, obesity, oropharyngeal tissues, size of the tongue, length of the soft palate, and size of the uvula, tonsils, and crowding of oropharyngeal area were other parameters of examination. All of the aforementioned parameters were normal. He had no reversible morphological upper airway abnormalities (enlarged tonsils) as assessed by ear, nose, and throat specialists. There was no nasal breathing problems. He had no medication that could influence respiration or sleep. His body mass index was 29.2 kg/m2. Sleep study showed RDI as 62.8 and oxygen desaturation index as 65.0. The patient could not tolerate CPAP because of the feeling of difficulty breathing out. So he was titrated by using bilevel device. Bilevel positive airway pressure (PAP) device was found efficient with the pressure of 13 cm H2O for inspiratory PAP and 9 cm H2O for expiratory PAP. Bilevel PAP treatment was recommended but the patient did not accept. It was decided for MAD treatment.

Maxillary and mandibular impressions were obtained with irreversible hydrocolloid impression material (Kromopan; Lascod, Firenze, Italy), and casts were obtained with the use of a dental stone type III (Moldano; Bayer Co., Leverkusen, Germany). The interocclusal records were obtained with the patients protruded 75% of their maximum protrusive movement. The method described by Taylor2 was used. Vertical dimension was increased by 3 mm. The acrylic resin bases were prepared with heat-polymerized acrylic resin (Meliodent, Heraeus Kulzer, Germany). When polymerization of the acrylic was complete, finishing and polishing were performed. The appliance was evaluated in the patient's mouth for any possible discomfort (Figs 1 and 2). The patient was able to breathe comfortably through the nasal airway and the breathing hole on the appliance. Instructions for use and care were provided at insertion. The patient was advised to wear the appliance for at least 6 hours during night, and was recalled 1 week later. At the first weekly review, the patients reported that his sleep at night had improved and daytime somnolence had diminished. The patient underwent PSG follow-up recordings after 1 week and the RDI was 27.5. For severe RDI, bilevel device was administered to the patient. Changes were evaluated during bilevel device treatment and RDI was 3.1 (Table 1).

RESULTS

A comparison of baseline and 1st week follow-up PSG with MAD and bilevel device data is shown in Table 1.

The patient with MAD reported a favorable sleeping pattern without any discomfort on evaluation appointments after 1 week. He reported that snoring, wake gasping, and choking were reduced drastically. The RDI significantly decreased from 62.7 to 27.5 with the appliance. Concerning sleep architecture, showing the quality of sleep, stages of N3 and rapid eye movement (REM) sleep showed an increase significantly. N3 sleep time increased from 42 minutes (8.7%) to 129 minutes (28.4%), RDI REM decreased from 78.0 to 26.4, RDI non-REM decreased from 60.9 to 27.6, and total RDI decreased from 62.7 to 27.5. The average oxygen saturation did not improve as expected initially. Oxygen desaturation index decreased from 65.0 to 29.0.

Fig. 1:

The patient's occlusion

IJEDS-6-35-g001.tif
Fig. 2:

With MAD

IJEDS-6-35-g002.tif

Table 1: Change in RDI and the other parameters with MAD and bilevel device use for severe OSA

      Diagnostic sleep test June 11, 2015With MAD June 19, 2015With bilevel PAP device June 22, 2015
Total recording time (min)532.0479.0447.0
Total sleep time (min)485.5454.0351.0
Sleep latency (min)1.513.013.0
REM latency (min)106.5179.055.0
Sleep efficiency (%)91.394.878.5
Total REM sleep time (min)50.0 min45.5 min128.5 min
      10.3%10.0%36.6%
Total stage N1 sleep time74.5 min21.0 min9.5 min
      15.3%4.6%2.7%
Total stage N2 sleep time319.0 min258.5 min114.0 min
      65.7%56.9%32.5%
Total stage N3 sleep time42.0 min129.0 min99.0 min
      8.7%28.4%28.2%
RDI REM78.026.41.9
RDI non-REM60.927.65.3
Total RDI62.7 (severe)27.5 (moderate)3.1 (mild)
Total number of obstructive apneas75213
Total number of mixed apneas2810
Total number of central apneas2000
Total number of hypopneas38418715
Maximum apnea duration (sec)46.518.518.1
Total respiratory events50720918
Mean SpO2 (%)949391
Lowest SpO2 (%)818886
RDI supine02.94.4
RDI right side189.22.7
RDI left side52.6261.92.8
RDI prone86.40
Oxygen desaturation index65.029.03.6
Mean heart rate726968

SpO2: Oxygen saturation by pulse oximeter; RDI: Apnea + hypopnea + RERA (Respiratory Effort Related Arousal)/hour

With bilevel device, total RDI significantly decreased from 62.7 to 3.1, RDI REM decreased from 78.0 to 1.9, and RDI non-REM decreased from 60.9 to 5.3. The average oxygen saturation did not improve as expected initially. Oxygen desaturation index decreased from 65.0 to 3.6.

DISCUSSION

Intraoral appliances are generally indicated for mild to moderate OSA as an alternative to CPAP or craniofacial surgery.4,7-11 Although CPAP is proved to be more efficient in treatment, it is not tolerated well by patients; therefore, intraoral appliances are frequently preferred3,5,12-16 as in this patient.

Treatment success is commonly defined by a reduction in RDI to <5 or <10 in addition to a <50% reduction in baseline RDI.5-8,17,18 The patient's RDI decreased from 62.7 to 27.5 with the oral appliance in use. The PSG results confirmed that the treatment was successful in accordance with the literature. The patient indicated that his quality of life had improved and that he was comfortable with the device. These findings show that patient benefited from the oral device. But it was not enough.

For most patients with OSA, CPAP is an effective therapy. However, for a subset of individuals, CPAP is either not effective or is poorly tolerated. Bilevel PAP is potentially capable of treating OSA at a lower mean pressure than CPAP and can help augment ventilation via pressure support.19,20

Bilevel PAP systems may be particularly helpful for patients with coexisting lung disease and those with excessive levels of carbon dioxide. These devices have a sensing feature that helps determine and vary the appropriate pressure depending on whether a person is breathing in or out. Greater pressure is needed on inhalation and less on exhalation. Because of this, bilevel device was preferred.

Both active treatments resulted in decreases in apnea and hypopnea index; bilevel device showed a greater effect.

CONCLUSION

This clinical report compared efficacy of MAD therapy and bilevel device therapy. Although oral appliances have been shown to be less effective than nasal CPAP therapy, these appliances should still be considered when patients are intolerant to CPAP or bilevel device treatment as our patient or had an unsuccessful surgery.

ACKNOWLEDGMENT

Authors would like to thank Hacettepe University and Sleep Disorders Center, Ataturk Chest Diseases, and Thoracic Surgery Training and Research Hospital.

Conflicts of interest

Source of support: Nil

Conflict of interest: None